Cargando…

Potential Future Use, Costs, and Value of Poliovirus Vaccines

Countries face different poliovirus risks, which imply different benefits associated with continued and future use of oral poliovirus vaccine (OPV) and/or inactivated poliovirus vaccine (IPV). With the Global Polio Eradication Initiative (GPEI) continuing to extend its timeline for ending the transm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Kimberly M., Kalkowska, Dominika A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984393/ https://www.ncbi.nlm.nih.gov/pubmed/32645244 http://dx.doi.org/10.1111/risa.13557

Ejemplares similares

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID‐19 in the United States
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
por: Thompson, Kimberly M., et al.
Publicado: (2023)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
por: Kalkowska, D. A., et al.
Publicado: (2019)

Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
por: Thompson, Kimberly M., et al.
Publicado: (2022)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Health economic analysis of antiviral drugs in the global polio eradication endgame
por: Badizadegan, Kamran, et al.
Publicado: (2023)

Polio by the Numbers—A Global Perspective( )
por: Badizadegan, Kamran, et al.
Publicado: (2022)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

The potential impact of expanding target age groups for polio immunization campaigns
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2014)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

The Case for Live Poliovirus Vaccination
por: Paul, John R.
Publicado: (1960)

Direct detection of polioviruses using a recombinant poliovirus receptor
por: Gerloff, Nancy, et al.
Publicado: (2021)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Estimating the Extent of Vaccine-Derived Poliovirus Infection
por: Wringe, Alison, et al.
Publicado: (2008)

Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks()
por: Estivariz, Concepcion F., et al.
Publicado: (2023)

Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine
por: Mvundura, Mercy, et al.
Publicado: (2019)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad
por: Gamougam, Kadidja, et al.
Publicado: (2021)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iloo2076mpk2nheb917828jtqb